But after Moderna made a similar request on Wednesday, officials began discussing whether that approval should also be expedited, the people with knowledge of the matter said.
The FDA declined to comment.
Moderna reported earlier this summer that its booster is 93 percent effective when given six months after the second dose, and the company has been in close contact with the FDA ever since about a possible approval of its syringe for all adults.
With Covid-19 cases in the United States up more than 20 percent in the past two weeks, some government officials also argued that clearing the vaccination before Thanksgiving would allow all adults to quickly get a booster vaccination, regardless of which one Vaccine you originally received.
The FDA is now expected to finalize approvals for both vaccines on Friday morning ahead of an afternoon meeting of the Centers for Disease Control and Prevention’s vaccine advisory panel, according to people familiar with the matter.
However, it is unclear how the CDC panel will react to the swift approval of Moderna’s booster shot. The external consultants – who are tasked with recommending who should receive the vaccines – were originally only planned to consider an expanded eligibility for Pfizer’s booster. The FDA’s move could raise concerns among some advisors that they are being asked to endorse the distribution of a second vaccine on a faster schedule than originally planned.
The CDC is not required to follow the panel’s advice on introducing vaccines, but traditionally it has followed his recommendations.